Celldex Announces Proposed Public Offering of Common Stock

Biotech firm seeks to raise funds for commercial launch and pipeline development

Apr. 2, 2026 at 7:18am

Got story updates? Submit your updates here. ›

Celldex Therapeutics, Inc. (Nasdaq: CLDX) has announced plans for an underwritten public offering of its common stock. The company intends to use the net proceeds to fund commercial readiness activities for the potential launch of its drug barzolvolimab, continue clinical development of its pipeline, and support general corporate purposes.

Why it matters

As a clinical-stage biotech company, Celldex's ability to raise capital through public offerings is crucial for advancing its drug candidates and bringing new treatments to market. The proposed offering signals the company's confidence in its pipeline and preparations for a potential commercial launch.

The details

Celldex plans to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares offered. The final terms of the offering will depend on market conditions at the time of pricing. The company intends to use the proceeds to fund commercial readiness for barzolvolimab, continue clinical development of its product candidates, grow its bispecific antibody platform, and support general corporate purposes.

  • Celldex announced the proposed public offering on April 1, 2026.
  • The company expects to grant the underwriters a 30-day option to purchase additional shares.

The players

Celldex Therapeutics, Inc.

A clinical-stage biotechnology company leading the science at the intersection of mast cell biology and the development of transformative therapeutics.

Leerink Partners

One of the joint bookrunning managers for the proposed public offering.

TD Cowen

The other joint bookrunning manager for the proposed public offering.

Got photos? Submit your photos here. ›

What’s next

The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

The takeaway

Celldex's proposed public offering signals its commitment to advancing its drug pipeline and preparing for a potential commercial launch, underscoring the company's strategic focus on developing transformative therapies for patients with severe inflammatory, allergic, and autoimmune diseases.